Introducing the mini-CAR Therapeutic: Advancing Precision Medicine

​

At Caravan Biologix, our focus is on leveraging the Mini-CAR technology to address critical human diseases. Our therapeutic platform provides a versatile foundation for developing nearly unlimited differentials of Mini-CAR that can be tailored to treat different human diseases, demonstrating our dedication to advancing healthcare on multiple fronts.

​

In addition to developing our own pipeline of Mini-CAR drugs, a key aspect of our strategy involves collaborating with other biotech companies, offering our platform for the development of their own Mini-CAR driven pipelines. The out licensing of our platform technology can result in the production of standalone therapies or co-therapeutics alongside their existing medicines, showcasing our commitment to advancing healthcare through strategic partnerships and collaborations.

​

In addition to licensing, we are actively utilizing the Mini-CAR platform to develop our own therapeutic pipeline, meticulously designed to enhance human health and showcase the platform's full range of druggable properties. This strategic approach ensures that our research not only benefits our own pipeline but also contributes to the broader understanding and utilization of the Mini-CARTM technology in the medical field.

​

Mini-CARs are innovative drug candidates designed to emulate the functions of immune cells. Our Mini-CAR pipeline is focused on precision targeting of specific diseases, with a particular emphasis on cancer therapy. We are exploring the potential of releasing perforins, granzymes, and p53 to solid tumor cancers, offering a more effective alternative to whole-cell-based treatments. Additionally, our approach involves restoring the immunomodulatory function of Natural Killer cells by targeting and releasing wild type granules, thereby preventing certain types of Hemophagocytic Lymphohistiocytosis (HLH). Furthermore, we are leveraging this technology to expanded clonal B-cell populations in systemic lupus erythematosus (SLE), addressing the underlying causes of this disease and aiming to improve patient outcomes.